Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
Small Cell Lung Cancer
DRUG: AT-101|DRUG: topotecan
Number of participants with adverse events., 13 months
complete or partial remission of disease, 16 months
Further Study Details provided by Ascenta: